Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy

Journal of Diabetes and its Complications

Volumn 28, Issue 6, 2014, Pages 887-893

  Bryzinski, Brian ^a   Allen, Elsie ^b   Cook, William ^a   Hirshberg, Boaz ^a  

^a ASTRAZENECA   (United Kingdom)

^b NOVO NORDISK INC   (United States)

Author keywords

Cardiovascular disease; Dipeptidyl peptidase 4 inhibitor; Dyslipidemia; Incretin; Statin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SAXAGLIPTIN; SIMVASTATIN; SULFONYLUREA; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DEATH; DIABETIC PATIENT; DIARRHEA; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; META ANALYSIS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADAMANTANE; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84908300264     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.07.006     Document Type: Article

References (50)

1. American Diabetes Association Standards of medical care in diabetes-2013 Diabetes Care 36 2013 S11 S66
2. M. Banach, M. Malodobra-Mazur, A. Gluba, N. Katsiki, J. Rysz, and A. Dobrzyn Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance Current Pharmaceutical Design 19 2013 4904 4912
3. A. Barnett DPP-4 inhibitors and their potential role in the management of type 2 diabetes International Journal of Clinical Practice 60 2006 1454 1470
4. A.H. Barnett, B. Charbonnel, M. Donovan, and D. Fleming Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin Current Medical Research and Opinion 28 2012 513 523
5. A. Bellia, S. Rizza, M.F. Lombardo, G. Donadel, R. Fabiano, and K. Andreadi Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy Atherosclerosis 223 2012 197 203
6. R. Bhome, and H. Penn Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction Diabetic Medicine 29 2012 693 694
7. B. Bryzinski, E. Allen, W. Cook, and B. Hirshberg Saxagliptin reduces HbA1c and is well tolerated in patients with type 2 diabetes receiving concomitant statin therapy Presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL 2013 (abstract 1333-P)
8. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610 10.1136/bmj.f2610
9. A.R. Chacra, G.H. Tan, A. Apanovitch, S. Ravichandran, J. List, and R. Chen Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial International Journal of Clinical Practice 63 2009 1395 1406
10. M.E. Cobble, and R. Frederich Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data Cardiovascular Diabetology 11 2012 6 10.1186/1475-2840-11-6
11. A.L. Culver, I.S. Ockene, R. Balasubramanian, B.C. Olendzki, D.M. Sepavich, and J. Wactawski-Wende Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Archives of Internal Medicine 172 2012 144 152
12. G. Danaei, L.A. Garcia Rodriguez, O. Fernandez Cantero, and M.A. Hernan Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival Diabetes Care 36 2013 1236 1240
13. R.A. DeFronzo, M.N. Hissa, A.J. Garber, J. Luiz Gross, R. Yuyan Duan, and S. Ravichandran The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 32 2009 1649 1655
14. J. Doucet, A. Chacra, P. Maheux, J. Lu, S. Harris, and J. Rosenstock Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus Current Medical Research and Opinion 27 2011 863 869
15. V. Fonseca, T. Zhu, C. Karyekar, and B. Hirshberg Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage Diabetes, Obesity & Metabolism 14 2012 365 371
16. R. Frederich, R. McNeill, N. Berglind, D. Fleming, and R. Chen The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial Diabetology and Metabolic Syndrome 4 2012 36 10.1186/1758-5996-4-36
17. A.Z. Fu, Q. Zhang, M.J. Davies, S.R. Pentakota, L. Radican, and T. Seck Underutilization of statins in patients with type 2 diabetes in US clinical practice: a retrospective cohort study Current Medical Research and Opinion 27 2011 1035 1040
18. B. Göke, B. Gallwitz, J. Eriksson, A. Hellqvist, and I. Gause-Nilsson Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial International Journal of Clinical Practice 64 2010 1619 1631
19. B. Göke, B. Gallwitz, J.G. Eriksson, A. Hellqvist, and I. Gause-Nilsson Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial International Journal of Clinical Practice 67 2013 307 316
20. R.R. Henry, S.R. Smith, S.L. Schwartz, S.R. Mudaliar, C.F. Deacon, and J.J. Holst Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes Diabetes, Obesity & Metabolism 13 2011 850 858
21. M.P. Hermans, T. Delibasi, I. Farmer, L. Lohm, P. Maheux, and P. Piatti Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study Current Medical Research and Opinion 28 2012 1635 1645
22. P. Hollander, J. Li, E. Allen, R. Chen, and CV181-013 Investigators Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone Journal of Clinical Endocrinology and Metabolism 94 2009 4810 4819
23. P.L. Hollander, J. Li, R. Frederich, E. Allen, R. Chen, and CV 181013 Investigators Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus Diabetes & Vascular Disease Research 8 2011 125 135
24. M. Jadzinsky, A. Pfutzner, E. Paz-Pacheco, Z. Xu, E. Allen, and R. Chen Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial Diabetes, Obesity & Metabolism 11 2009 611 622
25. N. Katsiki, and M. Banach Statins and the risk of diabetes: the debate Archives of Internal Medicine 172 2012 895 896 (author reply 896-897)
26. P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, and R. Peto Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
27. N. Matikainen, and M.R. Taskinen Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Current Cardiology Reports 14 2012 721 731
28. T. Matsumae, Y. Abe, G. Murakami, K. Ueda, and T. Saito Effects of glucose metabolism on aortic pulse wave velocity in hemodialysis patients with and without diabetes Hypertension Research 31 2008 1365 1372
29. J.M. Neutel, C. Zhao, and C.S. Karyekar Adding saxagliptin to metformin extended release (XR) or uptitration of metformin XR: efficacy on daily glucose measures Diabetes Therapy 4 2013 269 283
30. G.A. Nichols, and C.E. Koro Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients Clinical Therapeutics 29 2007 1761 1770
31. M. Nowicki, I. Rychlik, H. Haller, L. Warren, L. Suchower, and I. Gause-Nilsson Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment Diabetes, Obesity & Metabolism 13 2011 523 532
32. M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, and I. Gause-Nilsson Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study International Journal of Clinical Practice 65 2011 1230 1239
33. C.Y. Pan, W. Yang, C. Tou, I. Gause-Nilsson, and J. Zhao Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial Diabetes/Metabolism Research and Reviews 28 2012 268 275
34. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation 106 2002 1024 1028
35. A. Pfützner, E. Paz-Pacheco, E. Allen, B. Frederich, R. Chen, and for the CV181039 Investigators Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks Diabetes, Obesity & Metabolism 13 2011 567 576
36. K.M. Prasanna Kumar, S.M. Jain, C. Tou, and K.M. Schutzer Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study International Journal of Diabetes in Developing Countries 2014 10.1007/s13410-014-0191-1
37. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, and D.D. Waters Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
38. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein New England Journal of Medicine 359 2008 2195 2207
39. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
40. J. Rosenstock, C. Aguilar-Salinas, E. Klein, S. Nepal, J. List, and R. Chen Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes Current Medical Research and Opinion 25 2009 2401 2411
41. J. Rosenstock, J.L. Gross, C. Aguilar-Salinas, M. Hissa, N. Berglind, and S. Ravichandran Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with type 2 diabetes Diabetic Medicine 30 2013 1472 1476
42. J. Rosenstock, S. Sankoh, and J.F. List Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes Diabetes, Obesity & Metabolism 10 2008 376 386
43. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, and A.J. de Craen Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
44. A.J. Scheen, G. Charpentier, C.J. Ostgren, A. Hellqvist, and I. Gause-Nilsson Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes/Metabolism Research and Reviews 26 2010 540 549
45. S. Simsek, C.G. Schalkwijk, and B.H. Wolffenbuttel Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes - the CORALL study Diabetic Medicine 29 2012 628 631
46. K. Stenlof, I. Raz, J. Neutel, S. Ravichandran, N. Berglind, and R. Chen Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin Current Medical Research and Opinion 26 2010 2355 2363
47. K.S. Taylor, C.J. Heneghan, A.J. Farmer, A.M. Fuller, A.I. Adler, and J.K. Aronson All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large UK primary care database Diabetes Care 36 2013 2366 2371
48. J.L. White, P. Buchanan, J. Li, and R. Frederich A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy BMC Endocrine Disorders 14 1 2014 17 10.1186/1472-6823-14-17
49. W. Yang, C.Y. Pan, C. Tou, J. Zhao, and I. Gause-Nilsson Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial Diabetes Research and Clinical Practice 94 2011 217 224
50. B. Zinman Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? American Journal of Medicine 124 2011 S19 S34